JP7113826B2 - プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ - Google Patents

プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ Download PDF

Info

Publication number
JP7113826B2
JP7113826B2 JP2019532927A JP2019532927A JP7113826B2 JP 7113826 B2 JP7113826 B2 JP 7113826B2 JP 2019532927 A JP2019532927 A JP 2019532927A JP 2019532927 A JP2019532927 A JP 2019532927A JP 7113826 B2 JP7113826 B2 JP 7113826B2
Authority
JP
Japan
Prior art keywords
compound
nci
etoposide
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019532927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502182A5 (enExample
JP2020502182A (ja
Inventor
ダムシュトルップ，ラーズ
グロムバッカー，トマス
シレンベルク，クリスティアン
ヴァッシレフ，リュボミール
ジンマーマン，アストリッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2020502182A publication Critical patent/JP2020502182A/ja
Publication of JP2020502182A5 publication Critical patent/JP2020502182A5/ja
Application granted granted Critical
Publication of JP7113826B2 publication Critical patent/JP7113826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019532927A 2016-12-19 2017-12-18 プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ Active JP7113826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436046P 2016-12-19 2016-12-19
US62/436,046 2016-12-19
PCT/EP2017/083272 WO2018114776A1 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Publications (3)

Publication Number Publication Date
JP2020502182A JP2020502182A (ja) 2020-01-23
JP2020502182A5 JP2020502182A5 (enExample) 2021-02-04
JP7113826B2 true JP7113826B2 (ja) 2022-08-05

Family

ID=60915499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532927A Active JP7113826B2 (ja) 2016-12-19 2017-12-18 プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ

Country Status (8)

Country Link
US (1) US11246929B2 (enExample)
EP (1) EP3554495B1 (enExample)
JP (1) JP7113826B2 (enExample)
KR (1) KR102607967B1 (enExample)
AU (1) AU2017384134B2 (enExample)
CA (1) CA3047449C (enExample)
ES (1) ES3040063T3 (enExample)
WO (1) WO2018114776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3992189A4 (en) * 2019-06-27 2022-12-07 Medshine Discovery Inc. QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA PK INHIBITORS
WO2022143671A1 (zh) * 2020-12-28 2022-07-07 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525409A (ja) 2002-04-30 2005-08-25 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
CN1861050A (zh) 2006-06-21 2006-11-15 山东蓝金生物工程有限公司 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂
JP2016522190A (ja) 2013-05-11 2016-07-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アリールキナゾリン
JP2016533370A (ja) 2013-10-17 2016-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN102014913A (zh) 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
IN2014KN02601A (enExample) * 2012-04-24 2015-05-08 Vertex Pharma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525409A (ja) 2002-04-30 2005-08-25 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
CN1861050A (zh) 2006-06-21 2006-11-15 山东蓝金生物工程有限公司 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂
JP2016522190A (ja) 2013-05-11 2016-07-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アリールキナゾリン
JP2016533370A (ja) 2013-10-17 2016-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶

Also Published As

Publication number Publication date
KR102607967B1 (ko) 2023-11-29
WO2018114776A1 (en) 2018-06-28
US20190365896A1 (en) 2019-12-05
CA3047449A1 (en) 2018-06-28
ES3040063T3 (en) 2025-10-28
US11246929B2 (en) 2022-02-15
JP2020502182A (ja) 2020-01-23
AU2017384134B2 (en) 2022-03-24
CA3047449C (en) 2023-07-04
AU2017384134A1 (en) 2019-08-01
EP3554495A1 (en) 2019-10-23
KR20190099253A (ko) 2019-08-26
EP3554495B1 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP6575952B2 (ja) イブルチニブ併用療法
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
RU2747788C2 (ru) Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
US20250352598A1 (en) Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
US20240122921A1 (en) Methods for cancer therapy
JP7113826B2 (ja) プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
JP2024531492A (ja) Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
CN100475212C (zh) 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合
RU2785997C1 (ru) Комбинация ингибитора протеинкиназы и дополнительного химиотерапевтического средства
KR20250088372A (ko) Btk 분해제와 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
HK40061016A (en) Combination therapy for the treatment of uveal melanoma
CN117597124A (zh) 西奥罗尼及其联合用药治疗乳腺癌的用途
HK40011322B (en) Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a phy906 extract or a scutellaria baicalensis georgi (s) extract
HK40011322A (en) Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a phy906 extract or a scutellaria baicalensis georgi (s) extract
CN101198253A (zh) 治疗癌症的组合、方法和组合物
HK1227400B (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
HK1227400A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220726

R150 Certificate of patent or registration of utility model

Ref document number: 7113826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250